Translational research studies of erbB oncogenes: Selection strategies for breast cancer treatment

Cancer Letters

Volumn 118, Issue 2, 1997, Pages 143-151

  Brandt, Burkhard H ^a   Beckmann, Alf ^a,b   Gebhardt, Frank ^a,b   Rötger, Antje ^a   Jackisch, Christian ^a   Assmann, Gerd ^a   Zänker, Kurt S ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Average gene copy number; c erbB 2; egfr; Gene dosage effect; Metastasis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; RECEPTOR PROTEIN;

ARTICLE; BREAST CANCER; GENE DOSAGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIGENE FAMILY; ONCOGENE C ERB; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RNA TRANSLATION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DNA REPLICATION; DNA, NEOPLASM; GENE AMPLIFICATION; GENE DOSAGE; GENES, ERBB; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 0030830133     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00324-8     Document Type: Article

References (19)

1. P.M. Ravdin, G.C. Chamness, The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers, Gene 159 (1995) 19-27.
2. C.C. Benz, B.H. Brandt, K.S. Zänker, Gene diagnostics provide insights into breast cancer prognosis and therapy, Gene 159 (1995) 3-7.
3. D. Yu, M.-C. Hung, The Her-2/neu gene in human candcers, in: E.J. Freireich, S.A. Stass (Eds.), Molecular Basis of Oncology, Blackwell Science, Oxford, 1995, pp. 131-162.
4. B. Brandt, U. Vogt, C.M. Schlotter, C. Jackisch, R. Werkmeister, M. Thomas, M. von Eiff, U. Bosse, K.S. Zänker, G. Assmann, Prognostic relevance of aberrations of the erbB oncogenes in breast, ovarian, oral and lung cancer: double-differential PCR for clinical diagnosis, Gene 159 (1995) 35-42.
5. L.A. Loeb, Mutator phenotype may be required for multistage carcinogenesis, Cancer Res. 51 (1991) 3075-3079.
6. C.J. Wikstrand, L.P. Hale, S.K. Batra, M.L. Hill, P.A. Humphrey, S.N. Kurpad, R.E. McLendon, D. Moscatello, C.N. Pegram, C.J. Reist, Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas, Cancer Res. 55 (1995) 3140-3148.
7. D.K. Moscatello, M. Holgado-Madruga, A.K. Godwin, G. Ramirez, G. Gunn, P.W. Zoltick, J.A. Biegel, R.L. Hayes, A.J. Wong, Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors, Cancer Res. 55 (1995) 5536-5539.
8. J.T. Lin, M.S. Wu, C.T. Shun, W.J. Lee, J.C. Sheu, T.H. Wang, Occurrence of microsatellite instability in gastric carcinoma is associated with enhanced expression of c-erbB-2 oncoprotein, Cancer Res. 55 (1995) 1428-1430.
9. W.L. McGuire, Breast cancer prognostic factors: evaluation guidelines, J. Natl. Cancer Inst. 83 (1991) 154-155.
10. J. Gudmundsson, R.B. Barkardottir, G. Eiriksdottir, T. Baldursson, A. Arason, V. Egilsson, S. Ingvarsson, Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations, Br. J. Cancer 72 (1995) 696-701.
11. F. Kerangueven, L. Essioux, A. Dib, T. Noguchi, F. Allione, J. Geneix, M. Longy, R. Lindereau, F. Eisinger, M.J. Pébusque, J. Jaquemier, C. Bonaiti-Pellié, H. Sobol, D. Birnbaum, Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8, Oncogene 10 (1995) 1023-1026.
12. V. Orphanos, G.M. Gown, Y. Hey, J.M. Boyle, M. Santibanez-Koref, Proximal 6q, a region showing allele loss in primary breast cancer, Br. J. Cancer 71 (1995) 290-293.
13. D.D. Chi, A.V. Hing, C. Helms, T. Steinbrueck, S.K. Mishra, H. Donis-Keller, Two chromosome 7 dinucleotide repeat polymorphisms at gene loci epidermal growth factor receptor (EGFR) and pro alpha 2 (I) collagen (COL1A2), Hum. Mol. Genet. 1 (1992) 135.
14. A.J. Ekstrand, N. Sugawa, C.D. James, V.P. Collins, Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails, Proc. Natl. Acad. Sci. USA 89 (1992) 4309-4313.
15. T. Saphner, D.C. Tormey, R. Gray, Annual hazard rates of recurrence for breast cancer after primary therapy, J. Clin. Oncol. 14 (1996) 2738-2746.
16. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, W.J. Levin, S.G. Stuart, J. Udove, A. Ullrich, M.F. Press, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science 244 (1989) 707-712.
17. J.G.M. Klijn, P.M. Look, H. Portengen, J. Alexieva-Figusch, W.L.J. van Putten, J.A. Foekens, The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study, Breast Cancer Res. Treatment 29 (1994) 73-84.
18. L.B. Kinsel, E. Szabo, G.L. Greene, J. Konrath, G.S. Leight, K.S. McCarty Jr., Immunohistochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods, Cancer Res. 49 (1989) 1052-1056.
19. T. Dittmar, K.S. Zänker, Use of antisense mRNA producing plasmid constructs against sense mRNA c-erbB-2 results in a growth inhibition of a fraction of SKBR3 cells Cancer Gene Therapy Conference Supplement, Vol. 3, No. 6, 1996.